Marisol Vieites

TL;DR: Four new palladium(II) complexes with the formula Pd(L)(2), where L are quinoxaline-2-carbonitrile N(1),N(4)-dioxide derivatives, were synthesized as a contribution to the chemistry and pharmacology of metal compounds with this class of pharmacologically interesting bioreductive prodrugs.

TL;DR: In this paper, the authors reported the development of palladium and platinum metal complexes with 5-nitrofuryl-containing thiosemicarbazones (L) as bioactive ligands against T. cruzi and PTA (1,3,5-triaza-7-phosphaadamantane) as co-ligand.

TL;DR: The new vanadyl complex and VO(L)2 complexes showed excellent selective cytotoxicity in hypoxia, being no cytotoxic in oxia, and could be indicative that complexation of the quinoxaline-2-carbonitrile N1,N4-dioxide derivatives with vanadium could improve their bioavailability.

TL;DR: Novel ruthenium complexes synthesized with HL = bioactive 5-nitrofuryl containing thiosemicarbazones and PTA = 1,3,5-triaza-7-phosphaadamantane have been synthesized and fully characterized and could be a contribution in the search for metal compounds that could be active against multiple parasites.

TL;DR: The ruthenium-semicarbazide complex has been characterized by 1 H NMR and FTIR spectroscopies and X-ray diffraction methods as discussed by the authors.